Suchergebnisse - "Mayer, Katharina A."

PubPharm (26)

1

Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection : Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena

enthalten in: Transplantation | 2023

von Borski, A. | Eskandary, F. | Haindl, S. | +9

2

Morphologic and Molecular Features of Antibody-Mediated Transplant Rejection : Pivotal Role of Molecular Injury as an Independent Predictor of Renal Allograft Functional Decline

enthalten in: Transplant international : official journal of the European Society for Organ Transplantation | 2023

von Herz, C. | Diebold, M. | Kainz, A. | +5

3

Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection : Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10

enthalten in: Transplantation direct | 2022

von Mayer, K. | Doberer, K. | Halloran, P. | +8

4

Levels of donor-derived cell-free DNA and chemokines in BK polyomavirus-associated nephropathy

enthalten in: Clinical transplantation | 2022

von Mayer, K. | Omic, H. | Weseslindtner, L. | +12

5

Emerging drugs for antibody-mediated rejection after kidney transplantation : a focus on phase II & III trials

enthalten in: Expert opinion on emerging drugs | 2022

von Mayer, K. | Budde, K. | Jilma, B. | +2

6

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection : study protocol for a phase 2 trial

enthalten in: Trials | 2022

von Mayer, K. | Budde, K. | Halloran, P. | +16

7

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

enthalten in: Trials | 2022

von Mayer, K. | Budde, K. | Halloran, P. | +16

8

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

enthalten in: Trials | 2022

von Mayer, K. | Budde, K. | Halloran, P. | +16

9

Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant Outcome

enthalten in: Frontiers in immunology | 2022

von Vietzen, H. | Döhler, B. | Tran, T. | +11

10

Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials

enthalten in: Expert opinion on emerging drugs | 2022

von Mayer, K. | Budde, K. | Jilma, B. | +2